The suppressive effect of eugenol on breast and liver tumor growth

Abstract

0.36 mmol/L (48hrs), 0.16 mmol/L (48hrs). According to the result of wound healing assay, 24 hours later, space area of Hep3B (0.25 mmol/L) and MDA-MB-231 (0.25 mmol/L) was reduced 62% and 68% less than control group. Hep3B (0.0625, 0.125, 0.25 mmol/L) and MDA-MB-231 (0.125, 0.25 mmol/L) tested with eugenol test samples were suppressed in the G0/G1 stage through the detection of cell cycle analysis. As the result of PT-PCR test, eugenol suppressed the MDA-MB-231 (0.125, 0.25mmol/L) dose dependent. When it comes to Hep3B (0.0625, 0.125, 0.25 mmol/L), COX-2 pathway are inhibited in compared to control group. Conclusion: Eugenol has less toxity toward normal liver cell than liver cancer cell and effective suppression on breast and liver cancer cell. It inhibit the NF-κB and COX-2 pathway on MDA-MB-231 and Hep3B cell and suppress them dose dependent in the G0/G1 stage of cell cycle. Otherwise, eugenol restrain the immigration of tumor cell effectively in low treatment concentration. In conclusion, eugenol will be a potential application on the breast and liver cancer treatment. Hence, additional study may be necessary to investigate the mechanism of eugenol in vivo. Keywords: Eugenol, MDA-MB-231, Hep3B, Wound Healing, RT-PCR; Introduction: Eugenol(4-Allyl-2-methoxyphenol), a natural phenolic constituent of clove oil, has been found application in various industries. As a potential ideal ingredient in the new drug development, its range of pharmacological activities has been well-researched and includes antimicrobial, anti-inflammatory, analgesic, anti-oxidant and anticancer activities, amongst others. Previous studies showed that eugenol has a strong anticancer potential against melanoma, osteosarcoma, leukemia, gastric cancer, skin tumor and prostate cancer cells. According to the inhibition of eugenol on COX-2 and NF-κB activity, eugenol is supposed to be effective on breast and liver tumor growth. As a result, MDA-MB-231, Hep3B and BNL CL.2 cell was selected into this study. Methods: The study was performed in 4 phase. First, cell viability was detected by MTT assay. Then, cell cycle analysis was manufactured on FACS ARIAII. With the result of previous experiments wound healing test was performed. At last, tumor markers COX-2 and NF-κB on breast and liver tumor cell was verified through RT-PCR test. Results: As a result of MTT assay, EC50 of MDA-MB-231 and Hep3B were 0.55 mmol/L (24hrs), 0.30 mmol/L (24hrs)